Abstract
Purpose :
The Brain Injury associated Visual Impairment Impact Questionnaire (BIVI-IQ) is a recently developed 15-item patient reported outcome measure designed to assess the impact of visual impairment after brain injury on quality of life. It is increasingly recommended to measure quality of life in clinical practice. Any measure used in clinical practice should be acceptable and practical for patients. The aim of this analysis was to evaluate patient perception of the BIVI-IQ using the QQ-10, a validated tool designed to quantitatively measure face validity and utility.
Methods :
Stroke survivors with visual impairment were recruited through 18 NHS Hospitals and third sector adverts. There was no limitation on length of time post-stroke. The study involved completing questionnaire sets on three separate occasions. At the second visit the BIVI-IQ was completed followed by the QQ-10. The five Likert ratings of the QQ-10 were coded as strongly disagree=0 to strongly agree=4. The first six items (helped me communicate about my condition, relevant to my condition, easy to complete, included all the aspects of my condition I am concerned about, was enjoyable, would be happy to complete as part of routine care) were summed to create the value score, and the remaining four items (too long, embarrassing, complicated, upset me) summed to create the burden score.
Results :
A total of 271 participants completed the QQ-10 in relation to the BIVI-IQ; 63.8% by interview format and 36.2% self-completed. Of these participants, 62.7% were male, mean age was 66.0 (SD14.9) years and median time since stroke was 103.5 (IQR 32-430) days. A total of 254 had visual impairment as a direct result of stroke: 64 had a pre-existing visual impairment and, for 17, the stroke-related visual impairment had fully resolved. Visual impairment types included visual field loss (n=216), ocular motility defects (n=107), reading difficulty (n=73), reduced visual acuity (n=58), visual inattention (n=32) and visual perception deficits (n=31). The mean of the value score was 84.5% (SD13.4) and the burden score was 10.2% (SD14.3). The median of each item within value score was >3 (range 0–4) and the burden score was 0 (range 0–4).
Conclusions :
The high value and low burden scores indicate the BIVI-IQ has face validity for patients and is acceptable for use. Further psychometric analysis is now required to fully validate the BIVI-IQ.
This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.